Aldrich MS. Medical causes of disordered sleep. In: Sleep Medicine. New York, NY: Oxford University Press Inc; 1999:307-324.
Alexiev BA, Drachenberg CB, Papadimitriou JC. Endocrine tumors of the gastrointestinal tract and pancreas: grading, tumor size and proliferation index do not predict malignant behavior. Diagn Pathol. 2007;2:28.
Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271-2277.
Ardill JES, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer. 2003;10(4):459-462.
ARUP's Laboratory Test Directory. Chromogranin A:
0080469. http://www.aruplab.com/guides/ug/tests/0080469.jsp. Accessed December 1, 2010.
Bader TR, Semelka RC, Chiu VCY, Armao DM, Woosley JT. MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J Magn Reson Imaging. 2001;14(3):261-269.
Balon HR, Goldsmith SJ, Siegel BA, et al. Procedure guideline for somatostatin receptor scintigraphy with 111In-pentetreotide. J Nucl Med. 2001;42(7):1134-1138.
Banfield A, Green S, Ramage JK. Neuroendocrine tumour management: a team approach. Hosp Med. 2005;66(1):37-42.
Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M, eds. The Merck Manual. 18th ed. Whitehouse Station, NJ: Merck Research Laboratories; 2006:85-86.
Boudreaux JP, Putty B, Frey DJ, et al. Surgical treatment of advanced-stage carcinoid tumors. Ann Surg. 2005;241(6):839-846.
Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25(15):1967-1973.
Capdevila J, Salazar R. Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Targ Oncol. 2009;4(4):287-296.
Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998;352(9130):799-805.
Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144(4):645-653.
Chatzipantelis P, Salla C, Konstantinou P, Karoumpalis I, Sakellariou S, Doumani I. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors. A study of 48 cases. Cancer Cytopathol. 2008;114(4):225-262.
Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996;20(2):126-131.
Data on file. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 27, 2009 and 2010.
DRAXIMAGE MIBG [package insert]. Kirkland, Quebec, Canada: DRAXIMAGE, a division of DRAXIS Specialty Pharmaceuticals Inc; March 2006.
Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23(1):70-78.
Eriksson B, Öberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(suppl 1):33-38.
Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47(2):223-233.
Fazio N. Neuroendocrine tumours: the multidisciplinary approach. Cancer Imaging. 2004;4:S1-S4.
Ferolla P, Faggiano A, Mansueto G, et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest. 2008;31(3):277-286.
Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116(6):1464-1486.
Formica V, Wotherspoon A, Cunningham D, et al. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007;96(8):1178-1182.
Ghosh PK, O'Dorisio TM. Gastrointestinal hormones and carcinoid syndrome. In: Felig P, Frohman LA, eds. Endocrinology & Metabolism. 4th ed. New York, NY: McGraw-Hill; 2001:1317-1353.
Gibril F, Jensen RT. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Yale J Biol Med. 1997;70(2):509-522.
Grahame-Smith DG. What is the cause of the carcinoid flush? Gut. 1987;28(11):1413-1416.
Hanson MW, Feldman JM, Blinder RA, Moore JD, Coleman RE. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology. 1989;172(3):699-703.
InterScience Institute. Assays.
http://www.interscienceinstitute.com/index.php?book/c.
Accessed December 1, 2010.
Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685-690.
Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14(2):780-785.
Jensen RT. Endocrine tumors of the gastrointestinal tract and pancreas. In: Kasper DL, Fauci AS, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine. 16th ed. Vol II. New York, NY: McGraw-Hill, Medical Publishing Division; 2005:2220-2231.
Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1559-1574.
Jones NL, Judd HL. Menopause & postmenopause. In: DeCherney AH, Nathan L, eds. Current Obstetric & Gynecologic Diagnosis & Treatment. 9th ed. New York, NY: McGraw-Hill; 2002:1018-1040.
Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458-511.
Kaplan LM. Endocrine tumors of the gastrointestinal tract and pancreas. In: Isselbacher KJ et al, eds. Harrison's Principles of Internal Medicine. 13th ed. New York, NY: McGraw-Hill; 1994:1535–1542.
Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34(3):300-313.
Korse CM, Bonfrer JMG, Aaronson NK, Hart AAM, Taal BG. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology. 2009;89(3):296-301.
LabCorp. Chromogranin A.
https://www.labcorp.com/wps/portal/!ut/p/c1/hY1BDoIwEEXPwglmmNaxLIEQu7CEVCPt. Accessed December 1, 2010.
Mamikunian G, Vinik AI, O'Dorisio TM, Woltering EA, Go VLW. Diagnosing and treating gastroenteropancreatic tumors, including ICD-9 codes. In: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. 4th ed. Inglewood, CA: Inter Science Institute; 2009:1-46.
Martelli A, Ghiglioni D, Sarratud T, et al. Anaphylaxis in the emergency department: a paediatric perspective. Curr Opin Allergy Clin Immunol. 2008;8(4):321-329.
Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14(35):5377-5384.
Mayo Clinic. Mayo Medical Laboratories – Unit Code 83559: Chromogranin A, Serum.
http://www.mayomedicallaboratories.com/test-catalog/print.php?unit_code=83559. Accessed December 1, 2010.
McCormick D. Carcinoid tumors and syndrome. Gastroenterol Nurs. 2002;25(3):105-111.
McStay MKG, Caplin ME. Carcinoid tumour. Minerva Med. 2002;93(5):389-401.
Medline Plus Medical Encyclopedia. Carcinoid syndrome.
http://www.nlm.nih.gov/medlineplus/ency/article/000347.htm. Updated September 4, 2008. Accessed May 7, 2009.
Medline Plus Medical Encyclopedia. Irritable bowel syndrome.
http://www.nlm.nih.gov/medlineplus/ency/article/00246.htm. Updated August 22, 2008. Accessed May 7, 2009.
Medline Plus Medical Encyclopedia. MIBG scintiscan.
http://www.nlm.nih.gov/medlineplus/ency/article/003830.htm. Accessed April 29, 2010.
Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469-1492.
Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717-1751.
Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AKC. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol. 2006;40(7):572-582.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-959.
Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100(18):1282-1289.
Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1983;1(11):727-740.
Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348(11):1005-1015.
Mullen JT, Wang H, Yao JC, et al. Carcinoid tumors of the duodenum. Surgery. 2005;138(6):971-978.
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Stat Fact Sheets.
http://seer.cancer.gov/csr/1975_2004/results_merged/topic_prevalence.pdf. Accessed April 29, 2010 and September 30, 2009.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. V.1.2011.
Norheim I, Theodorsson-Norheim E, Brodin E, Öberg K. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. 1986;63(3):605-612.
Öberg K. Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med. 1997;70(5-6):501-508.
Öberg K, Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. In: Helle KB, Aunis D, eds. Chromogranins: Functional and Clinical Aspects. New York, NY: Kluwer Academic/Plenum Publishers; 2000:329-337.
O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hsiao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem. 1989;35(8):1631-1637.
Peracchi M, Conte D, Gebbia C, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol. 2003;148(1):39-43.
Quest Diagnostics. Chromogranin A.
http://www.questdiagnostics.com/hcp/qtim/testMenuSearch.do.#. Accessed December 1, 2010.
Ramage JK, Davies AHG, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl 4):iv1-iv16.
Reznek RH. CT/MRI of neuroendocrine tumors. Cancer Imaging. 2006;6:S163-S177.
Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151-160.
Ross A, Mehdizadeh S, Tokar J, et al. Double balloon enteroscopy detects small bowel mass lesions missed by capsule endoscopy. Dig Dis Sci. 2008;53(8):2140-2143.
Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumours with [111In]DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Q J Med. 1998;91(4):295-301.
Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med. 1989;320(7):444-447.
Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer. 2005;103(8):1587-1595.
Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signaling and metabolism in human disease. Neurogastroenterol Motil. 2007;19(suppl 2):25-31.
Steinmüller T, Kianmanseh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87(1):47-62.
Stridsberg M, Eriksson B, Öberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177(2):337-341.
Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89(4):471-476.
Toth-Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg. 2004;187(5):575-579.
van der Lely AJ, de Herder WW. Carcinoid syndrome: diagnosis and medical management. Arq Bras Endocrinol Metab. 2005;49(5):850-860.
van Tuyl SAC, van Noorden JT, Timmer R, Stolk MFJ, Kuipers EJ, Taal BG. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc. 2006;64(1):66-72.
Vinik AI, Thompson N, Eckhauser F, Moattari AR. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncologica. 1989;28(3):389-402.
von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993;329(15):1073-1078. Erratum in N Engl J Med. 1993;329(21):1592.
Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009;89(3):302-307.
Westberg G, Wängberg B, Ahlman H, Bergh CH, Beckman-Suurküla M, Caidahl K. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg. 2001;88(6):865-872.
Wiedenmann B, Pape U-F. From basic to clinical research in gastroenteropancreatic neuroendocrine tumor disease—the clinician-scientist perspective. Neuroendocrinol. 2004;80(suppl 1):94-98.
Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist. 2005;10(2):123-131.
